Evidence map›Paper›PMID 36826090›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer.

Bernhard Grubmüller, Nicolai A Huebner, Sazan Rasul, Paola Clauser, Nina Pötsch, Karl Hermann Grubmüller, Marcus Hacker, Sabrina Hartenbach, Shahrokh F Shariat, Markus Hartenbach and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 4 countries.

Bernhard GrubmüllerDepartment of Urology, Medical University of Vienna, 1090 Vienna, Austria.
Nicolai A HuebnerDepartment of Urology, Medical University of Vienna, 1090 Vienna, Austria.
Sazan RasulDepartment of Biomedical Imaging and Image Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-2898-3232
Paola ClauserDepartment of Biomedical Imaging and Image Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, 1090 Vienna, Austria.
Nina PötschDepartment of Biomedical Imaging and Image Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, 1090 Vienna, Austria.
Karl Hermann GrubmüllerDepartment of Urology and Andrology, University Hospital Krems, 3500 Krems, Austria.
Marcus HackerDepartment of Biomedical Imaging and Image Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0002-4222-4083
Sabrina HartenbachHistoConsultingHartenbach, 89081 Ulm, Germany.
Shahrokh F ShariatDepartment of Urology, Medical University of Vienna, 1090 Vienna, Austria.
Markus HartenbachDepartment of Biomedical Imaging and Image Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Pascal BaltzerDepartment of Biomedical Imaging and Image Guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, 1090 Vienna, Austria.
Medical University of Vienna · ATUniversitätsklinikum Krems · ATAl-Ahliyya Amman University · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate if imaging biomarkers derived from 3-Tesla dual-tracer [(18)F]fluoromethylcholine (FMC) and [

methodsWe assessed 77 biopsy-proven PC patients who underwent 3T dual-tracer PET/mpMRI followed by radical prostatectomy (RP) between 2014 and 2017. We performed a retrospective lesion-based analysis of all cancer foci and compared it to whole-mount histopathology of the RP specimen. The primary aim was to investigate the pretherapeutic role of the imaging biomarkers FMC- and PSMA-maximum standardized uptake values (SUVmax) for the prediction of csPC and to compare it to the mpMRI-methods and PI-RADS score.

resultsOverall, we identified 104 cancer foci, 69 were clinically significant (66.3%) and 35 were clinically insignificant (33.7%). We found that the combined FMC+PSMA SUVmax were the only significant parameters (

conclusionsCombined FMC+PSMA SUVmax seems to be a reliable parameter for the prediction of csPC and might overcome the limitations of PI-RADS scoring. Further prospective studies are necessary to confirm these promising preliminary results.

Indexed as

Prostatic NeoplasmsHumansMagnetic Resonance ImagingMalePositron-Emission TomographyPositron Emission Tomography Computed TomographyProspective StudiesRetrospective Studiesdual tracerimaging biomarkersPET/MRIprostate cancer

Identifiers

PMID36826090
PMCPMC9954891
OpenAlexW4318485911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.